Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Review, H2 2018

Publisher Name :
Date: 10-Jul-2018
No. of pages: 55

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Review, H2 2018

Summary

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) pipeline Target constitutes close to 14 molecules. The latest report Tumor Necrosis Factor Receptor Superfamily Member 18 - Pipeline Review, H2 2018, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Glucocorticoid induced tumor necrosis factor receptor or TNFRSF18 or AITR is a protein encoded by TNFRSF18 gene. TNFSF18 is involved in interactions between activated T-lymphocytes and endothelial cells and in the regulation of T-cell receptor-mediated cell death. It mediated NF-kappa-B activation via the TRAF2/NIK pathway.

The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 4 and 2 respectively. Report covers products from therapy areas Oncology which include indications Solid Tumor, Melanoma, Non-Small Cell Lung Cancer, Adenocarcinoma Of The Gastro esophageal Junction, Blood Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Lymphoma, Metastatic Melanoma, Metastatic Renal Cell Carcinoma and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

Furthermore, this report also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18)

- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics and enlists all their major and minor projects

- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Overview
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Companies Involved in Therapeutics Development
Ablynx NV
Apogenix AG
Bristol-Myers Squibb Co
Checkpoint Therapeutics Inc
GigaGen Inc
Incyte Corp
Leap Therapeutics Inc
MedImmune LLC
Merck & Co Inc
Novartis AG
OncoMed Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Drug Profiles
AVA-018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986156 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CK-302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Agonize GITR for Solid Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GWN-323 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCAGN-1876 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MEDI-1873 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-1248 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-4166 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Agonize GITR for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Agonize GITR for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Agonize GITR for Solid Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMP-336B11 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRX-518 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Dormant Products
Tumor Necrosis Factor Receptor Superfamily Member 18 (Glucocorticoid Induced Tumor Necrosis Factor Receptor or Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Product Development Milestones
Featured News & Press Releases
Apr 18, 2018: OncoMed Presents Preclinical Abstract on GITRL-Fc trimer (OMP-336B11) At The 2018 American Association for Cancer Research Annual Meeting
Apr 09, 2018: OncoMed to Present Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Cancer Research Annual Meeting
Jan 16, 2018: Leap Therapeutics Announces First Patient Dosed with TRX518 Combination Therapy in Advanced Solid Tumors Trial
Nov 13, 2017: Leap Therapeutics Provides Update on its Antineoplastic Drug Candidate TRX-518
Sep 13, 2017: OncoMed Doses First Patient with GITRL-Fc in Phase 1a Clinical Trial
Apr 05, 2017: OncoMed Highlights Data Presented on GITRL-Fc trimer at the American Association for Cancer Research Annual Meeting 2017
Apr 03, 2017: Leap Therapeutics Presents Non-clinical and Phase 1 Data for TRX518 at the 2017 AACR Annual Meeting
Mar 07, 2017: Agenus Announces Presentation on INCAGN01876 at the American Association for Cancer Research (AACR) 2017 Annual Meeting
Mar 01, 2017: Leap Therapeutics to Present Clinical Data on TRX518 at 2017 AACR Annual Meeting
Nov 12, 2016: Leap Therapeutics Presents Data from Phase 1 Study of GITR Agonist
Jun 22, 2016: Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-GITR Checkpoint Antibody INCAGN1876 in Patients with Solid Tumors
Jun 05, 2016: Leap Therapeutics Presents Data from Phase 1 Single Dose Safety Study of Anti-GITR Immunotherapy TRX518 in Patients with Advanced Relapsed or Refractory Solid Tumors at American Society of Clinical Oncology (ASCO) 2016 Annual Meeting
Apr 19, 2016: OncoMed Presents GITRL-Fc Research at the AACR Annual Meeting 2016
Apr 18, 2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate INCAGN01876 at the American Association for Cancer Research (AACR) 2016 Annual Meeting
Jan 21, 2016: Agenus Announces Clearance of Investigational New Drug Application by the FDA for anti-GITR Antibody
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Ablynx NV, H2 2018
Pipeline by Apogenix AG, H2 2018
Pipeline by Bristol-Myers Squibb Co, H2 2018
Pipeline by Checkpoint Therapeutics Inc, H2 2018
Pipeline by GigaGen Inc, H2 2018
Pipeline by Incyte Corp, H2 2018
Pipeline by Leap Therapeutics Inc, H2 2018
Pipeline by MedImmune LLC, H2 2018
Pipeline by Merck & Co Inc, H2 2018
Pipeline by Novartis AG, H2 2018
Pipeline by OncoMed Pharmaceuticals Inc, H2 2018
Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
Dormant Projects, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • 2018-2023 Global Intravesical Bacillus Calmette Consumption Market Report
    Published: 12-Jul-2018        Price: US 4660 Onwards        Pages: 135
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Intravesical Bacillus Calmette market for 2018-2023. Intravesical Bacillus Calmette is used to treat a certain type of bladder cancer. Bladder cancer is the growth of abnormal or cancerous cells on the inner lining of the bladder wall. BCG helps prevent the cancer from coming back in the bladder lining, and also reduces the risk of it becoming invasive.......
  • 2018 Top 5 Intravesical Bacillus Calmette Players in North America, Europe, Asia-Pacific, South America, Middle East and Africa
    Published: 12-Jul-2018        Price: US 4960 Onwards        Pages: 124
    Intravesical Bacillus Calmette is used to treat a certain type of bladder cancer. Bladder cancer is the growth of abnormal or cancerous cells on the inner lining of the bladder wall. BCG helps prevent the cancer from coming back in the bladder lining, and also reduces the risk of it becoming invasive. In the last several years, Global market of Intravesical Bacillus Calmette developed rapidly, with an average growth rate of 5.32%. In 2016, Global revenue of Intravesical Bacillus Calmette ......
  • 2018-2023 Global Pharmaceutical Intermediates Consumption Market Report
    Published: 12-Jul-2018        Price: US 4660 Onwards        Pages: 167
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Pharmaceutical Intermediates market for 2018-2023. Pharmaceutical intermediates are chemical material or chemical products, which could be applied in production of active pharmaceutical ingredients. Their production needs not production certification and they can be produced in ordinary chemical factory. There are many kinds of pharmaceutical intermediates,......
  • 2018 Top 5 Pharmaceutical Intermediates Players in North America, Europe, Asia-Pacific, South America, Middle East and Africa
    Published: 12-Jul-2018        Price: US 4960 Onwards        Pages: 144
    Pharmaceutical intermediates are chemical material or chemical products, which could be applied in production of active pharmaceutical ingredients. Their production needs not production certification and they can be produced in ordinary chemical factory. There are many kinds of pharmaceutical intermediates, such as cephalosporin intermediates, vitamin intermediates, quinolones intermediates, steroid intermediates, etc. This industry is affected by the economy and policy, so it's important......
  • Global and United States Recombinant Peptides Market Research by Company, Type & Application 2013-2025
    Published: 12-Jul-2018        Price: US 2000 Onwards        Pages: 117
    Summary Market Segment as follows: By Type Glucagon Calcitonin Others By Application Oncology Blood Disorders Infectious Diseases Autoimmune Diseases Others By Company Sandoz Pharma Stada Arzneimittel Amgen Hospira Actavis Cipla Ltd. Wockhardt Ltd. Biocon Ltd. The main contents of the report including: ......
  • 2018-2023 Global Mildronate Dihydrate Consumption Market Report
    Published: 12-Jul-2018        Price: US 4660 Onwards        Pages: 136
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Mildronate Dihydrate market for 2018-2023. Mildronate is a registered trademark of the Grindex. Its active substance is meldonium. Meldonium is a limited-market pharmaceutical, and is an ‘anti-ischemic' drug, which means it is used to treat inadequate blood-flow to the organs, especially the heart. It is primarily used to treat patients with heart condition......
  • 2018 Top 5 Mildronate Dihydrate Players in North America, Europe, Asia-Pacific, South America, Middle East and Africa
    Published: 12-Jul-2018        Price: US 4960 Onwards        Pages: 124
    Mildronate is a registered trademark of the Grindex. Its active substance is meldonium. Meldonium is a limited-market pharmaceutical, and is an ‘anti-ischemic' drug, which means it is used to treat inadequate blood-flow to the organs, especially the heart. It is primarily used to treat patients with heart conditions that affect the body's ability to deliver oxygen to the body. It helps to protect against tissue damage from angina attacks, chronic heart failure and disorders of brain circulation.......
  • Global Plasminogen Market Research Report 2018
    Published: 11-Jul-2018        Price: US 2900 Onwards        Pages: 97
    This report studies the global Plasminogen market status and forecast, categorizes the global Plasminogen market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China and other regions (India, Southeast Asia, Central & South America, and Middle East & Africa). The global Plasminogen market is valued at million US$ in 2017 and will reach million US$ by the end of 2025, growing at ......
  • Global Intravesical Bacillus Calmette Market by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 11-Jul-2018        Price: US 3480 Onwards        Pages: 130
    Intravesical Bacillus Calmette is used to treat a certain type of bladder cancer. Bladder cancer is the growth of abnormal or cancerous cells on the inner lining of the bladder wall. BCG helps prevent the cancer from coming back in the bladder lining, and also reduces the risk of it becoming invasive. Scope of the Report: This report focuses on the Intravesical Bacillus Calmette in global market, especially in North America, Europe and Asia-Pacific, South America, Middle Ea......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs